EHA2024 Hybrid Congress

Thank you all for joining us in Madrid for the 29th European Hematology Association Congress!

The EHA2024 Congress platform is now closed. You may browse selected content through the EHA Library, EHA Open access library.

EHA2024 gallery

Thank you to the esteemed faculty, delegates, and industry partners for their valuable contributions to the EHA2024 Hybrid Congress, which took place in Madrid and online from June 13–16.

EHA2024 Hybrid Congress

Registration

Register here

The registration fee for the ESH-EBMT-EHA-IPIG 3rd Translational Research Conference: Bone Marrow Failure and Leukaemia Predisposition Syndromes is:
– 600€ for fully trained
– 300€ for in-training *
– 300€ Allied Health Professionals
– 600€ for Corporate
*A proof will be requested to confirm your status.…

Abstract submission

Abstract submission is now closed. Abstracts guidelines:
– Your abstract has to be structured (eg Objectives, Methods, Results, Conclusions)
– Maximum number of words: 500
– Your abstract will be submitted to the peer review procedure.

EHA Guidelines by Topic

AL Amyloidosis
Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines (2021)
Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group (2022)
Anemia
Recommendations regarding splenectomy in hereditary hemolytic anemias (2017)
Management of…

EHA Ranking 2025

The information on this page is also available as a printable PDF. EHA Ranking 2025 — PDF version

Position 
Company 
Priority points 
Corporate Level 

1 
Johnson & Johnson  
1. 488,82  
Platinum  

2 
Bristol Myers Squibb  
1.

Corporate Sponsor Program

View the EHA Ranking 2025

"Alone we can do so little; together we can do so much.

Priority Points System

The Priority Points System is designed to recognize sponsors’ investment and continuous support for EHA activities, and are allocated for each sponsorship program and/or item.

Research & Mentoring

One of EHA’s key pillars is investing in future leaders in hematology.